By Cecilia Butini

Sanofi SA said Tuesday that it won't further advance the development of a messenger-RNA vaccine against Covid-19 and would instead focus on another type of shot, based on recombinant protein technology.

The French pharma major said it wouldn't make sense for it to advance its mRNA vaccine into a phase 3 trial, despite previously announcing positive results from a phase 1/2 trial.

"From a public-health perspective, mRNA Covid vaccines are widely available today and starting a placebo-controlled study in countries where vaccines are available would be extremely challenging," a company spokesman said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

September 28, 2021 04:13 ET (08:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Sanofi.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Sanofi.